NCT05734378 Prognosis of Cerebral Small Vessel Disease
| NCT ID | NCT05734378 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Cerebral Amyloid Angiopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2020-12-01 |
| Primary Completion | 2030-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2020-12-01 with a primary completion date of 2030-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation. The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients with SVD according to the type of index presentation.
Eligibility Criteria
Inclusion Criteria: * Hypertensive deep perforator arteriolopathy (DPA), clinically symptomatic with either ICH, ischaemic stroke, cognitive impairment or severe radiological manifestation (Fazekas ≥II) * Cerebral amyloid angiopathy (CAA according to modified Boston or Edinburgh criteria), clinically symptomatic with either ICH (including cSAH), amyloid spells, cognitive impairment or severe radiological manifestation (CMB≥2) * Other SVD (i.e. CADASIL or other sporadic or genetic SVD) Exclusion Criteria: * Life expectancy of \<6 months due to not-SVD related causes (i.e. cancer) * Patient is unlikely to attend follow-up visits
Contact & Investigator
David J Seiffge, Prof, MD
PRINCIPAL INVESTIGATOR
Department of Neurology, Inselspital Bern University Hospital
Frequently Asked Questions
Who can join the NCT05734378 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Cerebral Amyloid Angiopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05734378 currently recruiting?
Yes, NCT05734378 is actively recruiting participants. Contact the research team at studien.stroke@insel.ch for enrollment information.
Where is the NCT05734378 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT05734378 clinical trial?
NCT05734378 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is David J Seiffge, Prof, MD at Department of Neurology, Inselspital Bern University Hospital. The trial plans to enroll 900 participants.